Cocrystal Pharma (COCP) Competitors $1.73 -0.04 (-2.26%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends COCP vs. CLRB, CUE, SPRO, SLS, SBFM, GANX, VHAQ, ENTX, RAPT, and CTXRShould you be buying Cocrystal Pharma stock or one of its competitors? The main competitors of Cocrystal Pharma include Cellectar Biosciences (CLRB), Cue Biopharma (CUE), Spero Therapeutics (SPRO), SELLAS Life Sciences Group (SLS), Sunshine Biopharma (SBFM), Gain Therapeutics (GANX), Viveon Health Acquisition (VHAQ), Entera Bio (ENTX), RAPT Therapeutics (RAPT), and Citius Pharmaceuticals (CTXR). These companies are all part of the "pharmaceutical products" industry. Cocrystal Pharma vs. Cellectar Biosciences Cue Biopharma Spero Therapeutics SELLAS Life Sciences Group Sunshine Biopharma Gain Therapeutics Viveon Health Acquisition Entera Bio RAPT Therapeutics Citius Pharmaceuticals Cellectar Biosciences (NASDAQ:CLRB) and Cocrystal Pharma (NASDAQ:COCP) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, community ranking, profitability, earnings, analyst recommendations, valuation and risk. Does the MarketBeat Community favor CLRB or COCP? Cellectar Biosciences received 218 more outperform votes than Cocrystal Pharma when rated by MarketBeat users. However, 76.67% of users gave Cocrystal Pharma an outperform vote while only 55.92% of users gave Cellectar Biosciences an outperform vote. CompanyUnderperformOutperformCellectar BiosciencesOutperform Votes24155.92% Underperform Votes19044.08% Cocrystal PharmaOutperform Votes2376.67% Underperform Votes723.33% Which has higher earnings and valuation, CLRB or COCP? Cocrystal Pharma is trading at a lower price-to-earnings ratio than Cellectar Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCellectar BiosciencesN/AN/A-$37.98M-$2.53-0.80Cocrystal PharmaN/AN/A-$17.98M-$1.77-0.98 Do analysts rate CLRB or COCP? Cellectar Biosciences presently has a consensus target price of $21.00, indicating a potential upside of 934.48%. Cocrystal Pharma has a consensus target price of $7.00, indicating a potential upside of 304.62%. Given Cellectar Biosciences' higher possible upside, equities research analysts clearly believe Cellectar Biosciences is more favorable than Cocrystal Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cellectar Biosciences 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Cocrystal Pharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to CLRB or COCP? In the previous week, Cellectar Biosciences had 3 more articles in the media than Cocrystal Pharma. MarketBeat recorded 4 mentions for Cellectar Biosciences and 1 mentions for Cocrystal Pharma. Cellectar Biosciences' average media sentiment score of 1.00 beat Cocrystal Pharma's score of 0.00 indicating that Cellectar Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cellectar Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cocrystal Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders and institutionals have more ownership in CLRB or COCP? 16.4% of Cellectar Biosciences shares are held by institutional investors. Comparatively, 6.7% of Cocrystal Pharma shares are held by institutional investors. 3.7% of Cellectar Biosciences shares are held by company insiders. Comparatively, 25.6% of Cocrystal Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Which has more risk & volatility, CLRB or COCP? Cellectar Biosciences has a beta of 0.99, meaning that its share price is 1% less volatile than the S&P 500. Comparatively, Cocrystal Pharma has a beta of 1.42, meaning that its share price is 42% more volatile than the S&P 500. Is CLRB or COCP more profitable? Cellectar Biosciences' return on equity of 0.00% beat Cocrystal Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Cellectar BiosciencesN/A N/A -200.45% Cocrystal Pharma N/A -73.89%-64.03% SummaryCellectar Biosciences beats Cocrystal Pharma on 8 of the 14 factors compared between the two stocks. Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here Get Cocrystal Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for COCP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart COCP vs. The Competition Export to ExcelMetricCocrystal PharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$17.59M$7.02B$5.39B$8.53BDividend YieldN/A7.96%5.13%4.14%P/E Ratio-0.989.47113.8115.12Price / SalesN/A381.571,483.2593.03Price / CashN/A47.3339.6434.05Price / Book0.675.324.665.02Net Income-$17.98M$153.56M$119.06M$225.46M7 Day Performance-4.42%0.12%0.79%0.37%1 Month Performance-1.14%15.23%5.65%3.57%1 Year Performance-2.81%41.16%36.76%29.42% Cocrystal Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)COCPCocrystal Pharma2.7036 of 5 stars$1.73-2.3%$7.00+304.6%+4.2%$17.59MN/A-0.9810Positive NewsCLRBCellectar Biosciences2.7697 of 5 stars$2.03-3.3%$21.00+934.5%-14.7%$72.78MN/A-0.6610Earnings ReportShort Interest ↓News CoverageCUECue Biopharma4.6549 of 5 stars$1.48-5.1%$5.00+237.8%-24.8%$71.99M$8.30M-1.5360Positive NewsGap UpHigh Trading VolumeSPROSpero Therapeutics4.5912 of 5 stars$1.33+5.6%$7.00+426.3%+3.5%$71.80M$105.43M4.0346News CoverageHigh Trading VolumeSLSSELLAS Life Sciences Group1.9457 of 5 stars$1.23+11.8%$3.00+143.9%+25.0%$71.04M$1M-1.3416SBFMSunshine Biopharma1.2107 of 5 stars$3.02+0.3%N/A-89.5%$70.70M$30.48M-0.013News CoveragePositive NewsGANXGain Therapeutics3.7516 of 5 stars$2.65-1.1%$7.33+176.7%-17.1%$68.69M$50,000.00-2.0420Short Interest ↓VHAQViveon Health AcquisitionN/A$10.00flatN/AN/A$66.49MN/A0.002High Trading VolumeENTXEntera Bio2.8986 of 5 stars$1.88+3.3%$10.00+431.9%+170.4%$66.20M$130,000.00-7.2320Short Interest ↓Positive NewsGap UpHigh Trading VolumeRAPTRAPT Therapeutics3.6709 of 5 stars$1.89+6.8%$18.17+861.2%-84.3%$65.97M$1.53M-0.6180News CoverageCTXRCitius Pharmaceuticals2.3124 of 5 stars$0.36+5.8%$4.00+998.9%-53.4%$65.77MN/A-1.5220Positive News Related Companies and Tools Related Companies CLRB Competitors CUE Competitors SPRO Competitors SLS Competitors SBFM Competitors GANX Competitors VHAQ Competitors ENTX Competitors RAPT Competitors CTXR Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:COCP) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredNvidia warning urgentI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredNothing can stop this gold rallyAfter what's felt like nearly a decade of disappointing gains, gold is stronger than ever and continues to hit...Stansberry Research | SponsoredWall St. Legend: Millions of Americans About to Fall Out of the 1%Wall Street insider reveals the financial tidal wave about to knock millions of Americans out of the One Perce...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cocrystal Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cocrystal Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
